ImmunoInformatics, Journal Year: 2024, Volume and Issue: 14, P. 100037 - 100037
Published: May 10, 2024
Language: Английский
Cancer Cell International, Journal Year: 2024, Volume and Issue: 24(1)
Published: July 11, 2024
Abstract As one of the significant challenges to human health, cancer has long been a focal point in medical treatment. With ongoing advancements field medicine, numerous methodologies for therapy have emerged, among which oncolytic virus gained considerable attention. However, viruses still exhibit limitations. Combining them with various therapies can further enhance efficacy treatment, offering renewed hope patients. In recent research, scientists recognized promising prospect amalgamating diverse treatments, potentially surmounting restrictions singular approaches. The central concept this combined revolves around leveraging incite localized tumor inflammation, augmenting immune response immunotherapeutic efficacy. Through approach, patient's system better recognize and eliminate cells, simultaneously reducing evasion mechanisms against system. This review delves deeply into latest research progress concerning integration treatments its role types therapy. We aim analyze mechanisms, advantages, potential challenges, future directions combination By extensively exploring field, we instill fight cancer.
Language: Английский
Citations
13
Cancer Gene Therapy, Journal Year: 2024, Volume and Issue: 31(9), P. 1412 - 1426
Published: July 27, 2024
Colorectal cancer (CRC) is known to be resistant immunotherapy. In our phase-I clinical trial, one patient achieved a 313-day prolonged response during the combined treatment of oncolytic virotherapy and To gain deeper understanding potential molecular mechanisms, we performed comprehensive multi-omics analysis on this three non-responders. Our investigation unveiled that, initially, tumor microenvironment (TME) responder presented minimal infiltration T cells natural killer cells, along with relatively higher presence macrophages compared Remarkably, treatment, there was progressive increase in CD4
Language: Английский
Citations
5
Virology, Journal Year: 2025, Volume and Issue: unknown, P. 110444 - 110444
Published: Jan. 1, 2025
Language: Английский
Citations
0
Mathematical Biosciences & Engineering, Journal Year: 2024, Volume and Issue: 21(3), P. 3876 - 3909
Published: Jan. 1, 2024
<abstract><p>Bortezomib and oncolytic virotherapy are two emerging targeted cancer therapies. Bortezomib, a proteasome inhibitor, disrupts protein degradation in cells, leading to the accumulation of unfolded proteins that induce apoptosis. On other hand, uses genetically modified viruses (OVs) infect trigger cell lysis, activate anti-tumor response. Despite progress treatment, identifying administration protocols for therapeutic agents remains significant concern, aiming strike balance between efficacy, minimizing toxicity, administrative costs. In this work, optimal control theory was employed design cost-effective efficient co-administration bortezomib OVs could significantly diminish population cells via death program with NF$ \kappa $B-BAX-RIP1 signaling network. Both linear quadratic strategies were explored obtain practical treatment approaches by adapting necroptosis programs. Our findings demonstrated combination therapy commencing followed infusions yields an effective tumor-killing outcome. These results provide valuable guidance development clinical treatment.</p></abstract>
Language: Английский
Citations
2
Computers in Biology and Medicine, Journal Year: 2023, Volume and Issue: 165, P. 107362 - 107362
Published: Aug. 19, 2023
Language: Английский
Citations
3
ImmunoInformatics, Journal Year: 2024, Volume and Issue: 14, P. 100037 - 100037
Published: May 10, 2024
Language: Английский
Citations
0